ACM
LXRX icon

Acrisure Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Acrisure Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,861
Closed -$32.2K – 327
2022
Q4 		$32.2K Buy
+16,861
New +$35.9K 0.04% 253

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acrisure Capital Management's LXRX Position: Q1 2023 in Review

Acrisure Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2023, closing a stake of 16,861 shares — an estimated $32.2K sold.

Acrisure Capital Management first reported a position in LXRX in Q4 2022 and held it in 1 quarter. The position peaked at $32.2K in Q4 2022. 104 funds tracked by Wall St. Rank hold LXRX as of Q1 2023.

  • Acrisure Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Acrisure Capital Management sold 16,861 Lexicon Pharmaceuticals shares in Q1 2023, an estimated $32.2K.
  • Acrisure Capital Management first reported a position in Lexicon Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Acrisure Capital Management's Lexicon Pharmaceuticals position peaked at $32.2K in Q4 2022.
  • 104 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2023.

Based on Acrisure Capital Management's 13F filing for Q1 2023, filed 15 May 2023.